Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elise Siegert

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Rheumatology (Oxford, England)|December 3, 2019
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohortCarina Mihai, Oliver Distler, Ana Maria Gheorghiu, et al.
Autoimmunity Reviews|February 6, 2023
The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohortAmalia Colalillo, Anna-Maria Hoffmann-Vold, Chiara Pellicano, et al.
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
The Lancet. Rheumatology|January 17, 2024
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trialJens Y Humrich, Caroline von Spee-Mayer, Elise Siegert, et al.
Arthritis Research & Therapy|March 24, 2018
Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosisFlorian Weigold, Jeannine Günther, Moritz Pfeiffenberger, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Autoimmunity Reviews|December 16, 2019
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR databaseCamelia Frantz, Dorte Huscher, Jérôme Avouac, et al.
Rheumatology (Oxford, England)|November 22, 2022
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysisCorrado Campochiaro, Anna-Maria Hoffmann-Vold, Jerome Avouac, et al.
The Lancet. Rheumatology|January 24, 2024
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohortsSophie I E Liem, Maaike Boonstra, Saskia le Cessie, et al.
Frontiers in Immunology|June 27, 2022
Endothelin B Receptor Immunodynamics in Pulmonary Arterial HypertensionChristoph Tabeling, Carla R González Calera, Jasmin Lienau, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Rheumatology (Oxford, England)|December 3, 2019
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohortCarina Mihai, Oliver Distler, Ana Maria Gheorghiu, et al.
Autoimmunity Reviews|February 6, 2023
The role of TAPSE/sPAP ratio in predicting pulmonary hypertension and mortality in the systemic sclerosis EUSTAR cohortAmalia Colalillo, Anna-Maria Hoffmann-Vold, Chiara Pellicano, et al.
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
The Lancet. Rheumatology|January 17, 2024
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trialJens Y Humrich, Caroline von Spee-Mayer, Elise Siegert, et al.
Arthritis Research & Therapy|March 24, 2018
Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosisFlorian Weigold, Jeannine Günther, Moritz Pfeiffenberger, et al.
Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.
Autoimmunity Reviews|December 16, 2019
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR databaseCamelia Frantz, Dorte Huscher, Jérôme Avouac, et al.
Rheumatology (Oxford, England)|November 22, 2022
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: a EUSTAR database analysisCorrado Campochiaro, Anna-Maria Hoffmann-Vold, Jerome Avouac, et al.
The Lancet. Rheumatology|January 24, 2024
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohortsSophie I E Liem, Maaike Boonstra, Saskia le Cessie, et al.
Frontiers in Immunology|June 27, 2022
Endothelin B Receptor Immunodynamics in Pulmonary Arterial HypertensionChristoph Tabeling, Carla R González Calera, Jasmin Lienau, et al.
Pageof 8